Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Xenografts derived from the neoplastic tissues of children with rhabdomyosarcoma have been used in immune-deprived mice to examine the efficacy of agents known to be active against this disease, and in others that received either limited or no clinical evaluation. Two models were derived; xenografts were established from tumors obtained from either (a) untreated patients or (b) from patients who had become refractory to conventional therapy. Model a identified as being effective each of these clinically used agents: vincristine, dactinomycin, cyclophosphamide, and doxorubicin; mitomycin C and 5-(3,3-dimethyl-1-triazeno)-2-methylimidazole-4-carboxamide also showed activity, as did busulfan in one tumor line. Tumors derived from refractory patients were significantly less responsive to all agents examined.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002460:Cell Line; D002648:Child; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D005260:Female; D006801:Humans; D051379:Mice; D009368:Neoplasm Transplantation; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013934:Thymectomy; D013997:Time Factors; D014183:Transplantation, Heterologous; D014916:Whole-Body Irradiation
D000970:Antineoplastic Agents